Quest Diagnostics Inc vs GameStop Corp. — how do they compare? Quest Diagnostics Inc trades at $204 (market cap $22.80B), while GameStop Corp. trades at $22.57 (market cap $10.06B). The key difference: Quest Diagnostics Inc is far larger — about 2.3× GameStop Corp.'s market cap, and Quest Diagnostics Inc pays a 1.67% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| DGX | GME | |
|---|---|---|
Market Cap | $22.80B | $10.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $27.69 |
52-Week Low | $166.42 | $19.94 |
Enterprise Value | $28.82B | $6.04B |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GME trades at $22.03, up 1.61% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million and a profit margin of 3.43%. Recent news highlights the proposed eBay acquisition and a robust EBITDA outlook exceeding $600 million for fiscal 2026.
The outlook is mixed; fundamental improvements in profitability and strategic moves like the eBay bid offer potential upside, but bearish technicals and a majority hold rating from analysts suggest caution. Key risks include execution of the acquisition, competitive pressures from digital game distribution, and reliance on collectibles growth.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →